What is AATec?
AATec Medical is a biotechnology company focused on developing a product platform utilizing recombinant alpha-1 antitrypsin (AAT). This platform is engineered for the therapeutic treatment of a range of conditions, including inflammatory diseases, viral infections, and various rare diseases. The company's strategic approach to addressing these complex health challenges positions it within the competitive landscape of biopharmaceutical innovation.
How much funding has AATec raised?
AATec has raised a total of $3M across 1 funding round:
Angel/Seed
$3M
Angel/Seed (2023): $3M, investors not publicly disclosed
What's next for AATec?
The recent major strategic investment signifies a critical juncture for AATec, likely indicating a transition from early-stage development towards scaling operations and advancing its therapeutic candidates through clinical trials. This infusion of capital is expected to accelerate research and development efforts, potentially paving the way for broader market penetration and the realization of its ambitious goals in treating inflammatory and rare diseases.
See full AATec company page
